Back to mobile site

Barclays Reiterates Overweight Rating on Alnylam Pharmaceuticals (ALNY)

September 3, 2024 5:25 AM EDT Send to a Friend
Barclays analyst Gena Wang reiterated an Overweight rating and $295.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY).The analyst comments "Key ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login